Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis.
about
Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.Treatment discontinuation in multiple sclerosis: The French Web-based survey ALLIANCETwo decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV studyObservational study assessing demographic, economic and clinical factors associated with access and utilization of health care services of patients with multiple sclerosis under treatment with interferon beta-1b (EXTAVIA).Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice.Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort studyA Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple SclerosisThe MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosisImproving patient-physician dialog: commentary on the results of the MS Choices survey.Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management programThe optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV studyPersistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review.Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs.A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany.Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment.Patient characteristics associated with medication adherence.Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS surveyTreatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug.Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.Monitoring medication adherence in multiple sclerosis using a novel web-based tool: A pilot study.Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis.Comparative effectiveness of interferons in relapsing-remitting multiple sclerosis: a meta-analysis of real-world studies.Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries.The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.Processing speed and working memory training in multiple sclerosis: a double-blind randomized controlled pilot study.Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a.End-stage renal disease and adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among patients with diabetes.Adherence to disease-modifying therapies in patients with multiple sclerosis
P2860
Q33610126-A9D8A3E4-1E0D-44DF-93E0-F9343E737682Q33692801-1762C562-1F2D-497B-B867-3BBD4E9744B6Q34090086-413D882B-F594-4693-87DC-0E684184913CQ34184837-805E5930-D3BE-4356-B3FD-8E0531FE5887Q34566243-1F35989B-D456-4E78-A806-14C03D9BBC59Q34599540-34BF951D-549D-4608-B684-D171E1414ED8Q35091777-3AC0C597-29CB-41A1-B626-5FE5B8CC9F16Q35388991-9FF9CF5D-A1F5-46FE-A6C8-A41A4B7A665FQ35651621-8BEBC9A1-5B60-4012-A38D-FF2B2D0EFB4CQ35674845-D49BF3D3-B2C4-4679-A349-2E16C2FA3890Q35780959-0F9996B9-2AE8-4A23-B41A-1C18B2E40B0CQ35784295-2AA9AF74-F8E4-4002-A366-C7EFCFC393CBQ35827701-D5000AC6-F5EA-42F4-BB87-6C89DD264BB8Q35948187-4CE72FB5-28E5-4911-AA2E-5D9E278E9CA7Q36147567-083D40EF-B605-4B70-969F-D10FD740944CQ36393288-2F2643ED-16E5-49CE-9ABB-54E31AB00A89Q36667801-7136E368-C1FD-46BC-B4FB-FC20477D62EEQ36698871-5D6B9852-CF24-4803-94A7-5BFDDEE80BB2Q36861884-CF88E102-E7E9-4CED-8050-644B609CA338Q36954729-67EF7525-D286-4737-8641-7A56A11E31C7Q37027674-D55B0A4F-18E2-48A2-A355-D4E1BE2E212FQ37442365-8DA59D99-9311-4BAA-B14C-ABEF4EA50C95Q37573148-B793742D-A81D-4414-8CCD-825D4425D8F5Q37922644-C2E1AB89-EC01-4855-A11C-FB36FCB736B0Q38238548-E7F925FD-B93C-426D-98B7-93C537B6A075Q38413212-88B2319A-E677-42F5-9A7F-68F0F42A4AACQ38661416-1A1C5B5A-5CF5-4E27-B40B-D965D1824292Q39061969-585CABC0-33FF-42DE-9EC5-F7353C931907Q39962881-63FB4698-4492-47F6-8162-6AD066B8A10CQ40138163-FC065E46-2139-4117-B8FA-5CF9C280CB47Q40710140-89DDB2F3-583E-423B-B30C-D4971C7F5DE7Q41429220-AC6FE41E-23B6-414F-A33D-609A6B54D614Q47986992-6F1BC80B-1C6C-411B-AC96-BD7B8B7DE49DQ48064606-4E2FA4C8-DF8B-469F-9A54-8F00D9263486Q53662831-95267095-3743-44B4-B942-C11D995C3D54Q58712969-33314D63-D390-4154-A541-805951D4B56C
P2860
Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Comparison of adherence and pe ...... dministrative claims analysis.
@ast
Comparison of adherence and pe ...... dministrative claims analysis.
@en
Comparison of adherence and pe ...... dministrative claims analysis.
@nl
type
label
Comparison of adherence and pe ...... dministrative claims analysis.
@ast
Comparison of adherence and pe ...... dministrative claims analysis.
@en
Comparison of adherence and pe ...... dministrative claims analysis.
@nl
prefLabel
Comparison of adherence and pe ...... dministrative claims analysis.
@ast
Comparison of adherence and pe ...... dministrative claims analysis.
@en
Comparison of adherence and pe ...... dministrative claims analysis.
@nl
P2093
P2860
P356
P1476
Comparison of adherence and pe ...... dministrative claims analysis.
@en
P2093
Carole Dembek
Leigh Borton
Maria Lopez-Bresnahan
Rachel Halpern
Sonalee Agarwal
P2860
P356
10.2147/PPA.S15702
P407
P577
2011-01-20T00:00:00Z